A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

NCT07569081 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

192

Enrollment

INDUSTRY

Sponsor class

Conditions

VEXAS Syndrome

Interventions

DRUG: Momelotinib
DRUG: Glucocorticoids
DRUG: Placebo

Sponsor

GlaxoSmithKline